ABIOMED, Inc. (ABMD)’s Institutional Ownership In The September Quarter

ABIOMED, Inc. (NASDAQ:ABMD) recovered 56.05% of its value since hitting low of $207.5. The recent move of -3.38% drop pushed the stock to close at $323.8 when trading ended on 01/11/2019. At recent session, the prices were hovering between $320.52 and $334.1979. This company shares are 36.69% off its target price of $442.6 and the current market capitalization stands at $15.1B. The recent change has given its price a -1.33% deficit over SMA 50 and -29.57% deficit over its 52-week high. The stock witnessed -1.32% declines, -14.09% declines and -21.9% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ABMD’s volatility during a week at 4.62% and during a month it has been found around 5.18%.

ABIOMED, Inc. (ABMD) Top Holders

Institutional investors currently hold around $12.77 billion or 90.8% in ABMD stock. Look at its top three institutional owners. Vanguard Group Inc owns $1.5 billion in ABIOMED, Inc., which represents roughly 9.97% of the company’s market cap and approximately 11.79% of the institutional ownership. Similar statistics are true for the second largest owner, Primecap Management Co/Ca/, which owns 3,371,940 shares of the stock are valued at $1.09 billion. The third largest holder is Blackrock Inc., which currently holds $1.01 billion worth of this stock and that ownership represents nearly 6.69% of its market capitalization.

ABIOMED, Inc. 13F Filings

At the end of September reporting period, 263 institutional holders increased their position in ABIOMED, Inc. (NASDAQ:ABMD) by some 5,617,013 shares, 249 decreased positions by 4,696,606 and 74 held positions by 29,112,918. That puts total institutional holdings at 39,426,537 shares, according to SEC filings. The stock grabbed 70 new institutional investments totaling 976,525 shares while 60 institutional investors sold out their entire positions totaling 479,325 shares.

ABIOMED, Inc. (NASDAQ:ABMD) Insider Trades

Multiple company employees have indulged in significant insider trading. ABIOMED, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that VP, Global Sales & Marketing Howley Michael G has sold 10,000 shares of ABIOMED, Inc. (ABMD) in trading session dated Sep. 25, 2018. These shares are worth $4,325,000 and were traded at $432.5 each. The SEC filing shows that Greenfield Andrew J performed a sale of 5,000 shares. The VP Healthcare Solutions disposed these shares by way of transaction on Sep. 24, 2018. The company’s shares were given away at $420 per share worth to an income of some $2,100,000 on account of Greenfield Andrew J.

VP Healthcare Solutions, Greenfield Andrew J, sold 4,440 common shares of ABIOMED, Inc. (ABMD) in the open market. In a transaction dated Aug. 29, 2018, the shares were put up for sale at an average price of $395, raking in a sum of $1,753,800. After this sale, 50,924 common shares of ABMD are directly owned by the insider, with total stake valued at $16,489,191.

In the transaction dated Jul. 30, 2018, the great number of shares disposed came courtesy the COO; Weber David M disposed a total of 19,282 shares at an average price of $356.77, amounting to approximately $6,879,239. The insider now directly owns 163,339 shares worth $52,889,168.

ABIOMED, Inc. (ABMD) Analyst Guide

Several analysts have released their opinion on ABIOMED, Inc. (NASDAQ:ABMD), with 6 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 5 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.45 average brokerage recommendation.